Insurance News Articles
Google

Sunday, May 27, 2012
Search Insurance News  
Latest News » All Insurance News » Bupa Boosts Cancer Cover


Bupa Boosts Cancer Cover
Bupa, the leading international healthcare group, announces plans to improve the quality of its cancer cover by no longer selling corporate health insurance schemes which feature overall cost or time limits for cancer treatment.

LONDON, ENGLAND, March 27, 2011 /24-7PressRelease/ -- In an industry first, Bupa, the leading international healthcare group, has announced plans to improve the quality of its cancer cover by no longer selling corporate health insurance schemes which feature overall cost or time limits for cancer treatment.

Cancer treatment costs increased sharply in 2005 and 2006 due to the introduction of new drugs. In response to the concerns this caused about rising costs, the health insurance market developed financial benefit caps and time limits to restrict financial exposure for client businesses.

However, experience has shown that these limits mean that patients who claim on their policies can be left vulnerable at critical points in their treatment.

Once employees reach their benefit ceiling they face the possibility of having to change their treatment mid-stream. The varying cost of cancer drugs also makes it very difficult for patients to make informed choices about their treatment path, and its likely cost, at the point of diagnosis.

Dr Natalie-Jane Macdonald, managing director, Bupa Health and Wellbeing, explained: "We work closely with our clients to help them to provide their employees with the best quality healthcare at a sustainable affordable cost, and this remains a priority for us. We have developed better, fairer ways of controlling healthcare costs without compromising the experience and outcomes of patients at a difficult time in their lives."

In 2010 Bupa spent GBP18m on drugs that are not widely available elsewhere and it routinely funds cancer treatments that are approved by the European Medicines Agency. Bupa also makes prompt decisions to pay for experimental drugs when clinically appropriate.

Press Release Contact Information:

Samantha Maslen
Bupa
PR Contact
15-19 Bloomsbury Way
London, England
WC1A2BA
Voice: +44 (0)20 7656 2638
Website: Visit Our Website

Silver Prepaid MasterCard card
. . . . . . . . . . . . . . . . . . . . . . . . . .

Affordable & Effective Press Release Distribution